Revance Therapeutics (RVNC) Tops Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Revance Therapeutics Releases Second Quarter 2015 Results
August 6, 2015 4:02 PM EDTNEWARK, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ: RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today results for the second quarter ended June 30, 2015.
Recent Pipeline Highlights
Topical RT001 Aesthetic Indication for the Treatment of Lateral Canthal (Crow's Feet) Lines Announced plans to initiate a US Phase 3 pivotal study for the treatment of crow's feet lines using investigational drug product candidate RT001, a topical gel formulation of botulinum toxin type A. Topical RT001... More